UTI Healthcare Fund-Growth Option- Direct
Compare
Equity
Direct
Sector - Healthcare
NAV: ₹ 160.3 as on 27-01-2023
Fund Performance
125 people have invested ₹ 8.9L in mutual fund in the last three months
Fund Insights
In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given 1.01% return, outperforming this fund by 7.5%
In the last 3 years, DSP Healthcare Fund Direct Growth has given 24.3% return, outperforming this fund by 5.11%
In the last 5 years, Nippon India Pharma Fund - Direct Plan - Growth Plan has given 14.49% return, outperforming this fund by 3.6%
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
Pros
5Y returns in the top 25% of the category
Beats FD returns for both 3Y & 5Y duration
Cons
3Y returns in the bottom 25% of the category
Fund Performance as on (19-Jan-23)
About the Fund
UTI Healthcare Fund-Growth Option- Direct is an equity fund. This fund was started on 1 January, 2013. The fund is managed by V Srivatsa, Kamal Gada. The fund could potentially beat inflation in the long-run.
Key parameters
1) UTI Healthcare Fund-Growth Option- Direct has a NAV of ₹160.3461 as on 27-01-2023.
2) UTI Healthcare Fund-Growth Option- Direct has ₹691 Cr worth of assets under management (AUM) as on 30-11-2022 and is less than category average.
3) The fund has an expense ratio 1.46 %.
Fund Overview
Expense ratio | 1.46% |
Benchmark | S&P BSE Healthcare PR |
AUM | ₹691 Cr |
Inception Date | 1 January, 2013 |
Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 1% |
Lock In | No Lock-in |
TurnOver | 43.4% |
Fund Distribution as on (31-Dec-22)
Size breakup
Large cap
42%
Small cap
29.8%
Mid cap
26%
Sector Allocation
Health
98.3%
Basic Materials
1.7%
Top Holdings as on (31-Dec-22)
Equity Holdings32
Debt Holdings2
Holdings | Weight% | Holdings Trend | 1M Change |
|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 13.58% | 0% | |
Cipla Ltd | 8.54% | -3.5% | |
Dr Reddy's Laboratories Ltd | 6.65% | 0% | |
Apollo Hospitals Enterprise Ltd | 6.48% | 0% | |
Fortis Healthcare Ltd | 4.68% | 0% |
See all
What changed
in last one month
AUM decreased by 29.1 Cr in last 1M
Dec'22 return underperformed benchmark
Change in AUM
Dec'22
₹ 691.5 Cr
Nov'22
₹ 720.6 Cr
Oct'22
₹ 725.4 Cr
Fund Returns vs Benchmark
Dec'22
2.33%
5.37%
Nov'22
0.25%
2.63%
Oct'22
2.33%
5.37%
Fund Return
Benchmark Return
Concentration Analysis as on (31-Dec-22)
Winners & Losers as on (31-Dec-22)
Top Growth Drivers | 1M Return |
|---|---|
Suven Pharmaceuticals Ltd | 6.7% |
Abbott India Ltd | 3.9% |
Krishna Institute of Medical Sciences Ltd | 3.3% |
Peer Analysis
Fund Manager
V Srivatsa
Fund Manager of UTI Healthcare Fund-Growth Option- Direct, since 3 March 2017
Top funds managed
Kamal Gada
Fund Manager of UTI Healthcare Fund-Growth Option- Direct, since 2 May 2022
Top funds managed
AMC details
Fund House
UTI Asset Management Co Ltd
Total Schemes
Total AUM
₹1.68L Cr
as on 31-Dec-2022
Address
PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051
Phone
+912266786666
Email
service@uti.co.in
Fund Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 12.8% since inception which is less than its category average return of 15.5%
Fund Allocations
This fund has an allocation of 97.82% in Equity, 0.18% in Debt and 1.99% in Cash related instruments
AUM size ₹691 Cr
This fund has AUM of ₹691 Cr which is less than its category average of ₹ 1318 Cr
Expense Ratio 1.46%
This fund has an expense ratio of 1.46% which is less than its category average expense ratio of 1.54%
Frequently Asked Questions
The current NAV of UTI Healthcare Fund-Growth Option- Direct is 163.44 as on 19-Jan-2023.
Existing (Absolute + CAGR)
UTI Healthcare Fund-Growth Option- Direct | Absolute Returns | CAGR Returns |
1 Month Returns | -0.05% | -0.05% |
6 Month Returns | 1.76% | 1.76% |
1 Year Returns | -8.16% | -8.16% |
3 Years Returns | 72.81% | 20% |
5 Years Returns | 72.28% | 11.49% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.46 as on December 2022
691 Cr as on December 2022
Sun Pharmaceuticals Industries Ltd(13.58%),Cipla Ltd(8.54%),Dr Reddy's Laboratories Ltd(6.65%),Apollo Hospitals Enterprise Ltd(6.48%),Fortis Healthcare Ltd(4.68%) as on December 2022
Health(96.18%),Cash Equivalent(1.99%),Basic Materials(1.65%) as on December 2022
The alpha ratio for the UTI Healthcare Fund-Growth Option- Direct for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
UTI Healthcare Fund-Growth Option- Direct | -0.97 | 1.96 | 1.7 |
As on December 2022
The alpha for UTI Healthcare Fund-Growth Option- Direct is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the UTI Healthcare Fund-Growth Option- Direct for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
UTI Healthcare Fund-Growth Option- Direct | 0.93 | 0.93 | 0.91 |
As on December 2022
The Beta for UTI Healthcare Fund-Growth Option- Direct is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the UTI Healthcare Fund-Growth Option- Direct for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
UTI Healthcare Fund-Growth Option- Direct | -1.1 | 0.84 | 0.4 |
As on December 2022
The sharpe ratio for UTI Healthcare Fund-Growth Option- Direct is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the UTI Healthcare Fund-Growth Option- Direct for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
UTI Healthcare Fund-Growth Option- Direct | 14.53 | 21.09 | 19.19 |
As on December 2022
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.85 as on December 2022. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.31 as on December 2022. It tells the consistency of the fund in generating superior risk-adjusted performance
V Srivatsa,Kamal Gada are the fund managers of UTI Healthcare Fund-Growth Option- Direct
The Exit load of UTI Healthcare Fund-Growth Option- Direct is 1%
Mutual Fund execution provided by
Technology facilitation Services provided by Finzoom Investment Advisors Pvt. Ltd. - Advisory unit. SEBI Registered Investment Advisor: INA100012190 | BASL Registration No. 1154 | BSE StarMF Platform code: 24801
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not indicative of future returns.